Official websites use .gov

A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS

A lock ( 🔒 ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Need Help

Point-of-care viral load monitoring to support large-scale clinical testing of new HIV cure strategies

Award Number: R43AI181436
ORGANIZATION: NATIONAL INSTITUTE OF ALLERGY & INFECTIOUS DISEASES
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 04/01/2024
PERIOD OF PERFORMANCE END DATE: 03/31/2026

Group Awards By:

View Award Description

Point-of-care viral load monitoring to support large-scale clinical testing of new HIV cure strategies - ABSTRACT The global HIV epidemic has profoundly impacted public health. HIV affects tens of millions of people worldwide, including over a million in the United States. While antiretroviral therapy (ART) allows individuals to suppress the virus and live normal lives, it is expensive, has side effects, and requires lifelong adherence. The need for a cure has led to the development of new therapeutic strategies. However, large-scale clinical testing is hindered by the low virus concentration in blood during ART and the lack of sensitive, cost-effective point-of-care (POC) tests for measuring small changes in viral load on a regular basis. There is an urgent need for a test that can quantitatively differentiate between individuals maintaining suppression after stopping ART and those experiencing viral rebound, so as to enable quick detection of rebounds and re-initiation of therapy. The goal of the project proposed here is to develop a POC-compatible quantitative test for accurate viral load monitoring that could support large-scale clinical trials of HIV cure strategies. Our approach uses digital loop- mediated isothermal amplification (dLAMP), which has been shown to provide precise viral load measurements on raw, unpurified samples. Such capabilities make dLAMP well suited for POC settings. Our collaborative network, composed of engineers, clinical experts, and researchers, will collaborate to create a groundbreaking diagnostic platform that addresses major limitations in HIV testing and accelerates progress towards an HIV cure. By leveraging the combined expertise and resources, we will develop a cost-effective microfluidic consumable test and reusable assay instrument. Ultimately, this tool will improve HIV management and eradication efforts. This project will be led by Fluid Discovery, whose mission is to commercialize point-of-care pathogen diagnostics based on digital LAMP technology. Through the support of Professor Adam Abate, who will also guide development of the technology, the company will collaborate with UCSF and the Gladstone Institute investigators. These include Dr. Charles Chiu (Director of the CLIA-certified Pathogen Testing Lab) and Dr. Melania Ott (Director of Virology at the Gladstone Institute), who will support the validation process. Additionally, the project will involve collaborations with Dr. Steven Deeks (Director of the Delaney AIDS Research Enterprise to Find a Cure, which oversees and invests in clinical trials of new therapies) and Dr. Michael Busch (Director at Vitalant Research Institute). The project will utilize authentic biospecimens from the SCOPE and RAVEN trials. Working with Fluid Discovery, this team will apply the technology to demonstrate its utility for HIV load monitoring.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2026 ( Subtotal = $0 )
2026	2024	VIVID BIOINNOVATIONS, PBC	953 INDIANA ST	SAN FRANCISCO	CA	94107	SAN FRANCISCO	USA	Allergy and Infectious Diseases Research	000	1	5/26/2026	NEW	$0
														Subtotal = $0

Issue Date FY: 2024 ( Subtotal = $268,142 )
2024	2024	FLUID DISCOVERY, INC.	953 INDIANA ST	SAN FRANCISCO	CA	94107	SAN FRANCISCO	USA	Allergy and Infectious Diseases Research	000	1	4/1/2024	NEW	$268,142
														Subtotal = $268,142

Grand Total All Awards = $268,142

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Point-of-care viral load monitoring to support large-scale clinical testing of new HIV cure strategies

Award Number: R43AI181436

ORGANIZATION: NATIONAL INSTITUTE OF ALLERGY & INFECTIOUS DISEASES

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 04/01/2024

PERIOD OF PERFORMANCE END DATE: 03/31/2026

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer